Analysis of patient's X-ray exposure in hepatic chemosaturation procedures: a single center experience.
Chemosaturation
Inteventional radiology
Liver metastasis
Melanoma
Percutaneous hepatic perfusion
Regional therapy
Journal
BMC medical imaging
ISSN: 1471-2342
Titre abrégé: BMC Med Imaging
Pays: England
ID NLM: 100968553
Informations de publication
Date de publication:
13 09 2022
13 09 2022
Historique:
received:
22
09
2021
accepted:
23
08
2022
entrez:
13
9
2022
pubmed:
14
9
2022
medline:
16
9
2022
Statut:
epublish
Résumé
Hepatic chemosaturation is a technique in which a high dose of the chemotherapeutic agent melphalan is administered directly into the liver while limiting systemic side effects. We reviewed our institutional experience regarding patient's X-ray exposure caused by the procedure. Fifty-five procedures, performed between 2016 and 2020 in 18 patients by three interventional radiologists (radiologist), were analyzed regarding the patient's exposure to radiation. Dose-area-product (DAP) and fluoroscopy time (FT) were correlated with the experience of the radiologist and whether the preprocedural evaluation (CS-EVA) and the procedure were performed by the same radiologist. Additionally, the impact of previous liver surgery on DAP/FT was analyzed. Experienced radiologist require less DAP/FT (50 ± 18 Gy*cm There is a significant learning curve regarding the procedure of hepatic chemosaturation. Due to dose reduction the evaluation and chemosaturation therapy should be performed by the same radiologist. Procedures in patients with previous liver surgery require higher DAP/FT.
Sections du résumé
BACKGROUND
Hepatic chemosaturation is a technique in which a high dose of the chemotherapeutic agent melphalan is administered directly into the liver while limiting systemic side effects. We reviewed our institutional experience regarding patient's X-ray exposure caused by the procedure.
METHODS
Fifty-five procedures, performed between 2016 and 2020 in 18 patients by three interventional radiologists (radiologist), were analyzed regarding the patient's exposure to radiation. Dose-area-product (DAP) and fluoroscopy time (FT) were correlated with the experience of the radiologist and whether the preprocedural evaluation (CS-EVA) and the procedure were performed by the same radiologist. Additionally, the impact of previous liver surgery on DAP/FT was analyzed.
RESULTS
Experienced radiologist require less DAP/FT (50 ± 18 Gy*cm
CONCLUSION
There is a significant learning curve regarding the procedure of hepatic chemosaturation. Due to dose reduction the evaluation and chemosaturation therapy should be performed by the same radiologist. Procedures in patients with previous liver surgery require higher DAP/FT.
Identifiants
pubmed: 36100850
doi: 10.1186/s12880-022-00887-2
pii: 10.1186/s12880-022-00887-2
pmc: PMC9469537
doi:
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
165Informations de copyright
© 2022. The Author(s).
Références
Liver Transpl. 2007 Oct;13(10):1401-4
pubmed: 17902125
Cancer Imaging. 2019 May 30;19(1):31
pubmed: 31146793
Cells. 2021 Jan 05;10(1):
pubmed: 33466278
AJR Am J Roentgenol. 2013 Mar;200(3):645-51
pubmed: 23436857
Ann Surg. 1994 Jul;220(1):50-2
pubmed: 8024358
PLoS One. 2021 Jul 16;16(7):e0254817
pubmed: 34270628
Singapore Med J. 2012 May;53(5):329-31
pubmed: 22584973
Hepatogastroenterology. 1998 Nov-Dec;45(24):1961-5
pubmed: 9951848
Ann Surg Oncol. 1994 Sep;1(5):389-99
pubmed: 7850540
Surg Radiol Anat. 2006 Oct;28(5):468-73
pubmed: 16642277
Am J Surg. 1971 Oct;122(4):505-12
pubmed: 5098656
Liver Transpl. 2008 Aug;14(8):1180-4
pubmed: 18668651
In Vivo. 2018 Jan-Feb;32(1):179-184
pubmed: 29275317
Cancer Control. 2017 Jan;24(1):96-101
pubmed: 28178721
Adv Ther. 2017 Jan;33(12):2122-2138
pubmed: 27798773
Ann Surg. 2004 Jan;239(1):53-60
pubmed: 14685100
Eur Radiol. 2019 Apr;29(4):1882-1892
pubmed: 30255257
J Surg Oncol. 2014 Apr;109(5):434-9
pubmed: 24249545
J Am Coll Radiol. 2013 Jul;10(7):518-22
pubmed: 23827004
Cardiovasc Intervent Radiol. 2019 Oct;42(10):1441-1448
pubmed: 31089781
Rofo. 2014 Oct;186(10):937-44
pubmed: 24729409